LUNDBECK PHARMA A/S — Credit Rating and Financial Key Figures
CVR number: 56750215
Ottiliavej 9, 2500 Valby
tel: 43714274
Income statement (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | 19 163.00 | 16 497.00 | 16 955.00 | 15 968.00 | 18 343.00 |
| Other operating income | 35 681.00 | 39 584.00 | 39 362.00 | 34 937.00 | |
| Costs of manufacturing | -17 897.00 | -13 282.00 | -14 617.00 | -13 385.00 | -16 492.00 |
| Gross profit | 1 266.00 | 3 215.00 | 2 338.00 | 2 583.00 | 1 851.00 |
| Costs of management | -4 252.00 | -5 197.00 | -6 864.00 | -6 238.00 | -6 262.00 |
| Costs of distribution | -30 536.00 | -31 553.00 | -32 918.00 | -33 053.00 | -27 691.00 |
| Other operating expenses | -35 437.00 | ||||
| EBIT | 1 915.00 | 2 146.00 | 2 140.00 | 2 654.00 | 2 835.00 |
| Other financial income | 19.00 | 3.00 | 78.00 | 40.00 | 86.00 |
| Other financial expenses | -6.00 | -47.00 | -56.00 | -81.00 | - 115.00 |
| Reduction non-current investment assets | -6 295.00 | - 442.00 | |||
| Pre-tax profit | -4 367.00 | 2 102.00 | 2 162.00 | 2 171.00 | 2 806.00 |
| Income taxes | - 777.00 | - 860.00 | -1 180.00 | -1 180.00 | - 986.00 |
| Net earnings | -5 144.00 | 1 242.00 | 982.00 | 991.00 | 1 820.00 |
Assets (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Investments total | |||||
| Non-current loans receivable | 452.00 | 452.00 | 452.00 | 10.00 | 10.00 |
| Deferred tax assets | 141.00 | 193.00 | 99.00 | 151.00 | 274.00 |
| Long term receivables total | 593.00 | 645.00 | 551.00 | 161.00 | 284.00 |
| Inventories total | |||||
| Current trade debtors | 3 700.00 | 3 722.00 | 3 540.00 | 4 660.00 | 8 404.00 |
| Current amounts owed by group member comp. | 8 464.00 | 10 565.00 | 8 201.00 | 11 548.00 | 10 652.00 |
| Prepayments and accrued income | 1 085.00 | 897.00 | 306.00 | 287.00 | 271.00 |
| Current other receivables | 73.00 | 65.00 | 63.00 | 7.00 | |
| Current deferred tax assets | 163.00 | 87.00 | |||
| Short term receivables total | 13 485.00 | 15 336.00 | 12 047.00 | 16 558.00 | 19 334.00 |
| Balance sheet total (assets) | 14 078.00 | 15 981.00 | 12 598.00 | 16 719.00 | 19 618.00 |
Equity and liabilities (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Share capital | 500.00 | 500.00 | 500.00 | 500.00 | 500.00 |
| Shares repurchased | 1 242.00 | 982.00 | 991.00 | 1 820.00 | |
| Retained earnings | 3 044.00 | - 581.00 | - 144.00 | 53.00 | - 656.00 |
| Profit of the financial year | -5 144.00 | 1 242.00 | 982.00 | 991.00 | 1 820.00 |
| Shareholders equity total | -1 600.00 | 2 403.00 | 2 320.00 | 2 535.00 | 3 484.00 |
| Non-current other liabilities | 2 141.00 | ||||
| Non-current liabilities total | 2 141.00 | ||||
| Current trade creditors | 2 878.00 | 2 518.00 | 2 196.00 | 3 246.00 | 8 263.00 |
| Short-term deferred tax liabilities | 82.00 | 231.00 | 999.00 | ||
| Other non-interest bearing current liabilities | 12 800.00 | 8 919.00 | 8 000.00 | 10 707.00 | 6 872.00 |
| Current liabilities total | 15 678.00 | 11 437.00 | 10 278.00 | 14 184.00 | 16 134.00 |
| Balance sheet total (liabilities) | 14 078.00 | 15 981.00 | 12 598.00 | 16 719.00 | 19 618.00 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.